| Ident. | Authors (with country if any) | Title |
|---|
| 000138 |
Naomi P. Visanji [Canada] ; Jonathan M. Brotchie [Canada] ; Lorraine V. Kalia [Canada] ; James B. Koprich [Canada] ; Anurag Tandon [Canada] ; Joel C. Watts [Canada] ; Anthony E. Lang [Canada] | α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. |
| 000153 |
Qing He [République populaire de Chine] ; James B. Koprich [Canada] ; Ying Wang [République populaire de Chine] ; Wen-Bo Yu [République populaire de Chine] ; Bao-Guo Xiao [République populaire de Chine] ; Jonathan M. Brotchie [Canada] ; Jian Wang [République populaire de Chine] | Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. |
| 000157 |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; Gabriela Reyes [Canada] ; Vanessa Omana [Canada] ; Jonathan M. Brotchie [Canada] | Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson’s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque |
| 000551 |
Yilong Ma [États-Unis] ; Tom H. Johnston [Canada] ; Shichun Peng [États-Unis] ; Chuantao Zuo [République populaire de Chine] ; James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Yihui Guan [République populaire de Chine] ; David Eidelberg [États-Unis] ; Jonathan M. Brotchie [Canada] | Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. |
| 000641 |
Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Monoamine Reuptake Inhibitors in Parkinson's Disease |
| 000719 |
Sujoy Phookan [États-Unis] ; Alexander C. Sutton [États-Unis] ; Ian Walling [États-Unis] ; Autumn Smith [États-Unis] ; Katherine A. O'Connor [États-Unis] ; Joannalee C. Campbell [États-Unis] ; Megan Calos [États-Unis] ; Wilson Yu [États-Unis] ; Julie G. Pilitsis [États-Unis] ; Jonathan M. Brotchie [Canada] ; Damian S. Shin [États-Unis] | Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats. |
| 000877 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Katie D. Lewis [Australie] ; James B. Koprich [Canada] ; M Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. |
| 000933 |
Sherri L. Thiele [Canada] ; Betty Chen [Canada] ; Charlotte Lo [Canada] ; Tracey S. Gertler [États-Unis] ; Ruth Warre [Canada] ; James D. Surmeier [États-Unis] ; Jonathan M. Brotchie [Canada] ; Joanne E. Nash [Canada] | Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models |
| 000C43 |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Susan H. Fox ; Jonathan M. Brotchie | The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. |
| 000C50 |
James B. Koprich [Canada] ; Philippe Huot ; Susan H. Fox ; Keith Jarvie ; Anthony E. Lang ; Philip Seeman ; Jonathan M. Brotchie | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. |
| 000E88 |
Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials |
| 000F09 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tessa Snoeren [Pays-Bas] ; James B. Koprich [Canada] ; Michael P. Hill [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Use of catechol‐O‐methyltransferase inhibition to minimize L‐3,4‐dihydroxyphenylalanine‐induced dyskinesia in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐lesioned macaque |
| 000F36 |
Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis] | Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit |
| 001005 |
Alexander C. Sutton [États-Unis] ; Wilson Yu [États-Unis] ; Megan E. Calos [États-Unis] ; Lauren E. Mueller [États-Unis] ; Matthew Berk [États-Unis] ; Jenny Shim [États-Unis] ; Eric S. Molho [États-Unis] ; Jonathan M. Brotchie [Canada] ; Peter L. Carlen [Canada] ; Damian S. Shin [États-Unis] | Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat |
| 001038 |
James B. Koprich [Canada] ; Philippe Huot [Canada] ; Susan H. Fox [Canada] ; Keith Jarvie [Canada] ; Anthony E. Lang [Canada] ; Philip Seeman [Canada] ; Jonathan M. Brotchie [Canada] | The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques |
| 001116 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Michael N. Gandy [Australie] ; M. Gabriela Reyes [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Jonathan M. Brotchie [Canada] | The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset |
| 001191 |
Philippe Huot [Canada] ; Tom H. Johnston ; James B. Koprich ; Ahmed Aman ; Susan H. Fox ; Jonathan M. Brotchie | L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001293 |
Tom H. Johnston [Canada] ; Zak Millar ; Philippe Huot ; Keith Wagg ; Sherri Thiele ; Danielle Salomonczyk ; Christopher J. Yong-Kee ; Michael N. Gandy ; Matthew Mcildowie ; Katie D. Lewis ; Jordi Gomez-Ramirez ; Joohyung Lee ; Susan H. Fox ; Mathew Martin-Iverson ; Joanne E. Nash ; Matthew J. Piggott ; Jonathan M. Brotchie | A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. |
| 001413 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease |
| 001474 |
Olivier Rascol [France] ; Joaquim Ferreira [Portugal] ; Laurence Nègre-Pages [France] ; Santiago Perez-Lloret [France] ; Lucette Lacomblez [France] ; Monique Galitzky [France] ; Jean-Christophe Lemarié [France] ; Jean-Christophe Corvol [France] ; Jonathan M. Brotchie [Canada] ; Laura Bossi [France] | A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease |
| 001574 |
Philippe Huot [Canada] ; Susan H. Fox ; Jonathan M. Brotchie | The serotonergic system in Parkinson's disease. |
| 001608 |
Ruediger Hilker [Allemagne] ; Jonathan M. Brotchie [Canada] ; Joab Chapman [Israël] | Pros and cons of a prion-like pathogenesis in Parkinson's disease |
| 001723 |
Philippe Huot [Canada] ; Susan H. Fox ; Adrian Newman-Tancredi ; Jonathan M. Brotchie | Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? |
| 001743 |
Philippe Huot [Canada] ; Jonathan M. Brotchie | 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. |
| 001778 |
James B. Koprich [Canada] ; Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Allan Goodman [États-Unis] ; Bertrand Le Bourdonnec [États-Unis] ; Roland E. Dolle [États-Unis] ; Robert N. Dehaven [États-Unis] ; Diane L. Dehaven-Hudkins [États-Unis] ; Patrick J. Little [États-Unis] ; Jonathan M. Brotchie [Canada] | The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease |
| 001986 |
Susan H. Fox [Canada] ; Jonathan M. Brotchie | The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. |
| 001996 |
Tom H. Johnston [Canada] ; Susan H. Fox ; Matthew J. Mcildowie ; Matthew J. Piggott ; Jonathan M. Brotchie | Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. |
| 001A47 |
James B. Koprich [Canada] ; Tom H. Johnston [Canada] ; M Gabriela Reyes [Canada] ; Xuan Sun [Canada] ; Jonathan M. Brotchie [Canada] | Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease |
| 001B24 |
Michael N. Gandy [Australie] ; Matthew Mcildowie [Australie] ; Katie Lewis [Australie] ; Agata M. Wasik [Royaume-Uni] ; Danielle Salomonczyk [Canada] ; Keith Wagg [Australie] ; Zak A. Millar [Australie] ; David Tindiglia [Australie] ; Philippe Huot [Canada] ; Tom Johnston [Canada] ; Sherri Thiele [Canada] ; Blake Nguyen [Australie] ; Nicholas M. Barnes [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Mathew T. Martin-Iverson [Australie] ; Joanne Nash [Canada] ; John Gordon [Royaume-Uni] ; Matthew J. Piggott [Australie] | Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity |
| 001B51 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates |
| 001C09 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations |
| 001C36 |
Tom H. Johnston [Canada] ; Anne Van Der Meij [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Effect of histamine H2 receptor antagonism on levodopa–induced dyskinesia in the MPTP‐macaque model of Parkinson's disease |
| 001C77 |
Tom H. Johnston [Canada] ; Susan H. Fox [Canada] ; Matthew J. Piggott [Australie] ; Juha-Matti Savola [Suisse] ; Jonathan M. Brotchie [Canada] | The α2 Adrenergic Antagonist Fipamezole Improves Quality of Levodopa Action in Parkinsonian Primates |
| 001C89 |
Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada] | Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease |
| 001D05 |
Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations |
| 001F59 |
Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada] | Serotonin and Parkinson's disease: On movement, mood, and madness |
| 002158 |
Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. Brotchie | Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. |
| 002166 |
Susan H. Fox [Canada] ; Jonathan M. Brotchie ; Anthony E. Lang | Non-dopaminergic treatments in development for Parkinson's disease. |
| 002281 |
Joohyung Lee [Canada, Australie] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi Visanji [Canada] ; Jonathan M. Brotchie [Canada] | Receptor‐activity modifying protein 1 expression is increased in the striatum following repeated L‐DOPA administration in a 6‐hydroxydopamine lesioned rat model of Parkinson's disease |
| 002373 |
Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease |
| 002379 |
Anthony P. Nicholas [États-Unis] ; Farah D. Lubin [États-Unis] ; Penelope J. Hallett [États-Unis] ; Padmapriya Vattem [États-Unis] ; Paula Ravenscroft [Royaume-Uni] ; Erwan Bezard [France] ; SHAOBO ZHOU [Royaume-Uni] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] ; J. David Sweatt [États-Unis] ; David G. Standaert [États-Unis] | Striatal histone modifications in models of levodopa-induced dyskinesia |
| 002565 |
Giovanni Fabbrini [Italie] ; Jonathan M. Brotchie [Canada] ; Francisco Grandas [Espagne] ; Masahiro Nomoto [Japon] ; Christopher G. Goetz [États-Unis] | Levodopa‐induced dyskinesias |
| 002784 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa‐induced dyskinesia from MPTP‐lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure |
| 002813 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease |
| 002925 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 002947 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 002A01 |
Tom H. Johnston [Canada] ; Susan H. Fox ; Jonathan M. Brotchie | Advances in the delivery of treatments for Parkinson's disease. |
| 002A41 |
Jonathan M. Brotchie [Canada] | Nondopaminergic mechanisms in levodopa‐induced dyskinesia |
| 002B32 |
Katerina Venderov [Canada] ; Timothy M. Brown [Royaume-Uni] ; Jonathan M. Brotchie [Canada] | Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus |
| 002B51 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 002B89 |
Tom H. Johnston [Canada] ; Jonathan M. Brotchie | Drugs in development for Parkinson's disease. |
| 002D24 |
Erwan Bezard [France] ; Michael P. Hill [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Anne Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque |
| 002D94 |
Jonathan M. Brotchie [Canada] | CB1 cannabinoid receptor signalling in Parkinson's disease. |
| 002F10 |
Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada] | Presymptomatic compensation in Parkinson's disease is not dopamine-mediated |
| 002F16 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
